ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
Published in: | Annals of Oncology |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Elsevier BV
2018
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1093/annonc/mdy292.001 https://api.elsevier.com/content/article/PII:S0923753419497913?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753419497913?httpAccept=text/plain http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy292.001/26140262/mdy292.001.pdf |
Description not available. |